コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ies of ASB and GALNS are associated with the mucopolysaccharidoses.
2 treating CNS storage diseases, including the mucopolysaccharidoses.
3 isease, Fabry disease, Pompe disease and the mucopolysaccharidoses.
4 wo disease groups: glycosphingolipidoses and mucopolysaccharidoses.
5 lacement might prove beneficial for treating mucopolysaccharidoses.
6 g for use in substrate reduction therapy for mucopolysaccharidoses, a group of inherited metabolic di
7 biochemical and pathological features of the mucopolysaccharidoses and particularly features of mucop
10 e replacement therapy has been used to treat mucopolysaccharidoses; however, neuropathology has remai
11 , pathologic and biochemical features of the mucopolysaccharidoses, lysosomal storage diseases caused
16 glycan (GAG) storage in animal models of the mucopolysaccharidoses (MPS) leads to inflammation and ap
17 sult in lysosomal storage disorders known as mucopolysaccharidoses (MPS), causing severe pathology, p
22 rapy is currently available for three of the mucopolysaccharidoses (MPSs) but has limited effects on
23 bclass of lysosomal storage disorders called mucopolysaccharidoses (MPSs), many of which present with
25 (CLN1 or CLN2 deficiency, respectively) and mucopolysaccharidoses type VII (MPS VII), a deficiency o
26 us systemic diseases, such as hemophilia and mucopolysaccharidoses types I and VII, has encountered s
27 teoglycans beyond their association with the mucopolysaccharidoses, we modified the expression of ASB
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。